Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bictegravir/Lenacapavir vs Biktarvy in Virologically Suppressed People With HIV-1
NCT06333808Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of bictegravir + lenacapavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) >= 50 Copies/mL at 144 weeks. Started Mar 2024; status: active, not recruiting.
02
Drugs
bictegravir + lenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06333808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333808.